Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell

Marco Herling1

  • 1Laboratory of Lymphocyte Signaling and Oncoproteome, Center for Integrated Oncology (CIO) Köln-Bonn and Cologne Cluster of Excellence in Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.

Abstract

No abstract available in PubMed .